A new low-dose formulation of selegiline: Clinical efficacy, patient preference and selectivity for MAO-B inhibition

Journal of Neural Transmission

Volumn 110, Issue 11, 2003, Pages 1257-1271

  Clarke, A ^a,f   Johnson, E S ^a,g   Mallard, N ^a,h   Corn, T H ^b   Johnston, A ^c   Boyce, M ^d   Warrington, S ^d   MacMahon, D G ^e  

^a Scherer DDS   (United Kingdom)

^b Elan Pharma Ltd   (United Kingdom)

^c QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^d CENTRAL MIDDLESEX HOSPITAL   (United Kingdom)

^e Camborne Redruth Hospital ^*  (United Kingdom)

^f Cephalon UK Ltd   (United Kingdom)

^g Safetymednet ^*  (United Kingdom)

^h Oxford GlycoSciences   (United Kingdom)

Author keywords

MAO A; MAO B; Metabolites; Otrasel ; Selectivity; Selegiline; Therapeutic equivalence; Xilopar ; Zelapar

Indexed keywords

AMINE OXIDASE (FLAVIN CONTAINING) ISOENZYME B; DOPAMINE; LEVODOPA; META TYRAMINE; OTRASEL; SELEGILINE; XILOPAR;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOSE RESPONSE; DRUG FORMULATION; DRUG SELECTIVITY; DRUG SOLUBILITY; DRUG TOLERABILITY; ENZYME INHIBITION; FEMALE; HUMAN; HUMAN EXPERIMENT; MAJOR CLINICAL STUDY; MALE; MOTOR PERFORMANCE; MUCOSA INFLAMMATION; NORMAL HUMAN; PARKINSON DISEASE; PATIENT ATTITUDE; PRESSOR RESPONSE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SALIVATION;

ADMINISTRATION, ORAL; ADULT; AGED; DOPAMINE AGONISTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; LEVODOPA; MALE; MIDDLE AGED; MONOAMINE OXIDASE; MONOAMINE OXIDASE INHIBITORS; PARKINSON DISEASE; PATIENT SATISFACTION; REFERENCE VALUES; SELEGILINE; TREATMENT OUTCOME; TYRAMINE;

EID: 0344758978     PISSN: 03009564     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00702-003-0042-6     Document Type: Article

References (41)

1. Birkmayer W, Riederer P, Youdim MB, Linauer W (1975) The potentiation of the anti akinetic effect after L-dopa treatment by an inhibitor of MAO-B, Deprenyl. J Neural Transm 36: 303-326
2. Birkmayer W, Knoll J, Riederer P, Youdim MB (1983) (-)-Deprenyl leads to prolongation of L-dopa efficacy in Parkinson's disease. Mod Prob1 Pharmacopsychiatry 19: 170-176
3. Birkmayer W, Knoll J, Riederer P (1985) Increased life expectancy resulting from addition of L-Deprenyl to Madopar treatment in Parkinson's disease: a longterm study. J Neural Transm 64: 113-127
4. Bine JE, Frank EM, McDade HL (1995) Dysphagia and dementia in subjects with Parkinson's disease. Dysphagia 10: 160-164
5. Brust JCM (ed) (1993) Neurological aspects of substance abuse. Butterworth-Heineman, London
6. Churchyard A, Mathias CJ, Boonkongchuen P, Lees AJ (1997) Autonomic effects of selegiline: possible cardiovascular toxicity in Parkinson's disease. J Neurol Neurosurg Psychiatry 63: 228-234
7. Clarke A, Johnson ES (1997) Pharmacodynamic equivalence of 1.25 mg Zydis selegiline (Zelapar™) and 10 mg selegiline tablets. European Neurological Society, Nice, France, June 1997 (Poster)
8. Clarke A, Brewer F, Johnson ES, Kelly EA (1997) Zydis Selegiline: evidence for rapid pregastric absorption of Selegiline. American Neurological Association, San Diego, USA, September 1997 (Poster)
9. Clarke A, Brewer F, Johnson ES, Mallard N, Hartig F, Taylor S, Corn TH (2003) A new formulation of selegiline: improved bioavailability and selectivity for MAO-B inhibition. J Neural Transm 110: 1241-1255
10. Edwards LL, Pfeiffer RF, Quigley EMM, Hofman R, Balluff M (1991) Gastrointestinal symptoms in Parkinson's disease. Mov Disord 6: 151-156
11. Fowler JS, Volkow ND, Logan J, Wang GJ, MacGregor RR, Schyler D, Wolf AP, Pappas N, Alexoff D, Shea C et al. (1994) Slow recovery of human brain MAO B after L-deprenyl (Selegiline) withdrawal. Synapse 18: 86-93
12. Gerlach M, Riederer P, Youdim MBH (1992) The molecular pharmacology of L-deprenyl. Eur J Pharmacol 226: 97-108
13. Green AR, Mitchell BD, Tordoff AFC, Youdim MBH (1977) Evidence for dopamine deamination by both type A and type B monoamine oxidase in rat brain in vivo and for the degree of inhibition necessary for increased functional activity of dopamine and 5-hydroxytryptamine. Br J Pharmac 60: 343-349
14. Guttman M (1997) Double-blind comparison of pramipexole and bromocriptine treatment with placebo in advanced Parkinson's disease. International Pramipexole-Bromocriptine Study Group. Neurology 49: 1060-1065
15. Haberle D, Szoko E, Magyar K (2002) The influence of metabolism on the MAO-B inhibitory potency of selegiline. Curr Med Chem 9: 47-51
16. Jones B, Jarvis P, Lewis JA, Ebbutt AF (1996) Trials to assess equivalence: the importance of rigorous methods. BMJ 313: 36-39
17. Knoll J (1983) Deprenyl (selegiline): the history of its development and pharmacological action. Acta Neurol Scand 95: 57-80
18. Kurihara K, Kita K, Hirayama K, Hara Y (1993) Dysphagia in Parkinson's disease. Clin Neurol 33: 150-154
19. Lamensdorf I, Youdim MBH, Finberg JPM (1996) Effect of long-term treatment with selective monoamine oxidase A and B inhibitors of dopamine release from rat striatum in vivo. J Neurochem 67: 1532-1539
20. Leopold A, Kagel DO, Kagel MC (1996) Prepharyngeal dysphagia in Parkinson's disease. Dysphagia 11: 14-22
21. Mahmood I (1997) Clinical pharmacokinetics and pharmacodynamics of selegiline. An update. Clin Pharmacokinet 33: 91-102
22. Maki-Ikola O, Kilkku O, Heinonen E (1996) Effect of adding selegiline to levodopa in early, mild Parkinson's disease. BMJ 312: 702-705
23. Olanow CW, Jenner P, Youdim M (eds) (1996) Neurodegeneration and neuroprotection in PD. Academic Press, New York
24. Olanow CW, Watts RL, Koller WC (2001) An algorithm (decision tree) for the management of Parkinson's disease. Neurology 56[Suppl 5]: S1-S88
25. Oreland L, Yuichiro A, Stenstrom A (1983) The effect of deprenyl (selegiline) on intra-and extraneuronal dopamine oxidation. Acta Neurol Scand 95: 81-85
26. Parkinson's study group (1989) Effect of deprenyl on the progression of disability in early Parkinson's disease. Parkinson Study Group. N Engl J Med 321: 1364-1371
27. Parkinson Study Group (1993) Effects of tocopherol and deprenyl on the progression of disability in early Parkinson's disease. N Engl. J Med 328: 176-183
28. Parkinson Study Group (1996) Impact of deprenyl and tocopherol treatment on Parkinson's disease in DATATOP subjects not requiring levodopa. Ann Neurol 39: 29-36
29. Pickar D, Cohen RM, Jimerson DC, Raymond Lake C, Murphy DL (1981) Tyramine infusions and selective monoamine oxidase inhibitor treatment II. Interrelationships among pressor sensitivity changes, platelet MAO inhibition, and plasma MHPG reduction. Psychopharmacology 74: 8-12
30. Riederer P, Youdim MBH (1986) Monoamine oxidase activity and monoamine metabolism in brains of parkinsonian patients treated with L-deprenyl. J Neurochem 46: 1359-1365
31. Rinne UK, Bracco F, Chouza C, Dupont E, Gershanik O, Marti Masso JF, Montastruc JL, Marsden CD (1998) Early treatment of Parkinson's disease with cabergoline delays the onset of motor complications. Results of a double-blind levodopa controlled trial. The PKPDS009 Study Group. Drugs 55[Suppl 1]: 23-30
32. Schulzer M, Mak E, Calne DB (1992) The antiparkinsonian effect of deprenyl derives from transient improvement that is likely to be symptomatic. Ann Neurol 32: 795-798
33. Sen NP (1969) Analysis and significance of tyramine in foods. J Food Sci 34: 22-51
34. Singer C, Weiner WJ, Sanchez-Ramos JR (1992) Autonomic dysfunction in men with Parkinson's disease. Eur Neurol 32: 134-140
35. Stern G (1998) Neuroprotection by selegiline and other MAO inhibitors. J Neural Transm [Suppl 52]: 99-107
36. Themann C, Alvarez Fischer D, Gross S, Westermann R, Weihe E, Kuschinsky K, Schafer H, Ferger B (2002) Effect of repeated treatment with high doses of selegiline on behaviour, striatal dopaminergic transmission and tyrosine hydroxylase mRNA levels. Naunyn Schmiedebergs Arch Pharmacol 365: 22-28
37. Ulm G, Fornadi F (1987) R(-) deprenyl in the treatment of end-of-dose-akinesia. J Neural Transm [Suppl 25]: 163-172
38. Wang H, Wang Y, Wang D, Cui L, Tian S, Zhang Y (2002) Cognitive impairment in Parkinson's disease revealed by event-related potential N270. J Neurol Sci 194: 49-53
39. Warrington S, Turner P, Mant T et al. (1991) Clinical pharmacology of moclobemide, a new reversible monoamine oxidase inhibitor. J Psychopharmacol 5: 82-91
40. Warrington S, Boyce M, Rolfe L et al. (1998a) Higher availability of selegiline from Zydis® than Deprenyl® formulations does not lead to increased potentiation of the pressor response to oral tyramine. Br J Clin Pharmacol 46: 284P
41. Warrington S et al. (1998b) Are the metabolites of selegiline, rather than the parent compound, responsible for the potentiation of the pressor response to oral tyramine? Br J Clin Pharmacol 46: 297P